Evidence map›Paper›PMID 34089850›Full record

SynthesisClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022

Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.

Calen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, Peter D R Higgins, Jason R Spence, Carol Shannon, Cathy Lu, Ryan W Stidham, Joel G Fletcher, David H Bruining and 6 more

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Crohn Disease Strictures: Multimodality Imaging to Identify Imaging Biomarkers.Radiographics : a review publication of the Radiological Society of North America, Inc · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Intestinal strictures in Crohn's disease: An update from 2023.United European gastroenterology journal · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Calen A SteinerDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Electronic address: calen.steiner@cuanschutz.edu.
Jeffrey A BerinsteinDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Jeremy LouissaintDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Peter D R HigginsDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Jason R SpenceDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan.
Carol ShannonTaubman Health Sciences Library, University of Michigan, Ann Arbor, Michigan.
Cathy LuDivision of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Ryan W StidhamDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan.
Joel G FletcherDepartment of Radiology, Mayo Clinic, Rochester, Minnesota.
David H BruiningDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Brian G FeaganAlimentiv Inc, London, Ontario, Canada; Department of Medicine, Western University, London, Ontario, Canada; Department of Biostatistics and Epidemiology, Western University, London, Ontario, Canada.
Vipul JairathAlimentiv Inc, London, Ontario, Canada; Department of Medicine, Western University, London, Ontario, Canada; Department of Biostatistics and Epidemiology, Western University, London, Ontario, Canada.
Mark E BakerSection of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Dominik BettenworthDepartment of Medicine B, Gastroenterology and Hepatology, University of Münster, Münster, Germany.
Florian RiederDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium
University of Michigan · USCleveland Clinic · USMayo Clinic · USWestern University · CAUniversity of Calgary · CAUniversity of Münster · DE

Funding

Trade-offs in human observer performance, image quality metrics, and patient doseR01EB017095 · NIBIB · MAYO CLINIC ROCHESTER · PI Hao Gong, Cynthia H McCollough · 2012 to 2026
$7.0M
Training Program in Gastrointestinal EpidemiologyT32DK062708 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter D.R. Higgins, Elliot Tapper · 2003 to 2026
$3.9M
Training in Basic and Translational Digestive SciencesT32DK094775 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JOHN Y KAO, LINDA C. SAMUELSON · 2012 to 2026
$3.6M
Nonlinear Ultrasound: an Imaging Biomarker of Intestinal Fibrosis in Crohn's DiseaseR01DK109032 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DILLMAN, JONATHAN RUSSELL, HIGGINS, PETER D.R. · 2016 to 2019
$2.4M
Inhibiting Bcl-2-regulated intestinal fibrosis in models of Crohn’s DiseaseR01DK118154 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HIGGINS, PETER D.R. · 2018 to 2022
$2.3M
Automated Measurement of Bowel Damage Using Enterography Imaging to Predict Clinical Outcomes in Crohn’s Disease.R01DK124779 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STIDHAM, RYAN WILLIAM · 2020 to 2023
$2.1M
Creeping fat and Crohn's disease associated stricturesR01DK123233 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI RIEDER, FLORIAN · 2020 to 2024
$1.9M
Quantitative Ultrasound Imaging Biomarkers of Crohn's DiseaseR01DK120559 · NIDDK · MAYO CLINIC ROCHESTER · PI BRUINING, DAVID HENRY, CHEN, SHIGAO · 2019 to 2022
$1.7M
Dissemination of a Software Platform for Efficient CT Radiation Dose Optimization and Diagnostic Performance AssessmentU24EB028936 · NIBIB · MAYO CLINIC ROCHESTER · PI YU, LIFENG · 2019 to 2023
$1.6M
Microbiota in Intestinal FibrosisK08DK110415 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI RIEDER, FLORIAN · 2016 to 2020
$767k
NIBIB NIH HHS R01 EB017095NIBIB NIH HHS U24 EB028936NIDDK NIH HHS K08 DK110415NIDDK NIH HHS R01 DK109032NIDDK NIH HHS R01 DK118154NIDDK NIH HHS R01 DK120559NIDDK NIH HHS R01 DK123233NIDDK NIH HHS R01 DK124779NIDDK NIH HHS T32 DK062708NIDDK NIH HHS T32 DK094775
6 · The paper itself

Abstract

BACKGROUND AND

aimsIntestinal strictures are a common complication of Crohn's disease (CD). Biomarkers of intestinal strictures would assist in their prediction, diagnosis, and monitoring. Herein we provide a comprehensive systematic review of studies assessing biomarkers that may predict or diagnose CD-associated strictures.

methodsWe performed a systematic review of PubMed, EMBASE, ISI Web of Science, Cochrane Library, and Scopus to identify citations pertaining to biomarkers of intestinal fibrosis through July 6, 2020, that used a reference standard of full-thickness histopathology or cross-sectional imaging or endoscopy. Studies were categorized based on the type of biomarker they evaluated (serum, genetic, histopathologic, or fecal).

resultsThirty-five distinct biomarkers from 3 major groups were identified: serum (20 markers), genetic (9 markers), and histopathology (6 markers). Promising markers include cartilage oligomeric matrix protein, hepatocyte growth factor activator, and lower levels of microRNA-19-3p (area under the curves were 0.805, 0.738, and 0.67, respectively), and multiple anti-flagellin antibodies (A4-Fla2 [odds ratio, 3.41], anti Fla-X [odds ratio, 2.95], and anti-CBir1 [multiple]). Substantial heterogeneity was observed and none of the markers had undergone formal validation. Specific limitations to acceptance of these markers included failure to use a standardized definition of stricturing disease, lack of specificity, and insufficient relevance to the pathogenesis of intestinal strictures or incomplete knowledge regarding their operating properties.

conclusionsThere is a lack of well-defined studies on biomarkers of intestinal stricture. Development of reliable and accurate biomarkers of stricture is a research priority. Biomarkers can support the clinical management of CD patients and aid in the stratification and monitoring of patients during clinical trials of future antifibrotic drug candidates.

Indexed as

Crohn DiseaseIntestinal ObstructionMicroRNAsBiomarkersCartilage Oligomeric Matrix ProteinConstriction, PathologicHumansSerine EndopeptidasesBiomarkersCartilage Oligomeric Matrix ProteinHGF activatorMicroRNAsMIRN19A microRNA, humanSerine EndopeptidasesBiomarkerCrohn’s DiseaseFibrosisFibrostenosisIBDInflammatory Bowel DiseaseStenosisStricture

Identifiers

PMID34089850
PMCPMC8636551
OpenAlexW3169449709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.